Can removing the primary tumor extend control in EGFR-Mutant lung cancer?

This phase III trial is investigating whether surgically removing the primary lung tumor, in addition to continuing the targeted therapy osimertinib, can prolong the time before disease progression in patients with EGFR-mutant non-small cell lung cancer that has spread to a limited number of sites. Participants first receive osimertinib for 12 weeks; those with a response or stable disease are then randomly assigned to either continue osimertinib alone or undergo surgery to remove the primary tumor followed by resuming osimertinib. The study will compare progression-free survival, overall survival, safety, and quality of life between the two groups.